Associated Papers
miRNA Expression May Have Implications for Immunotherapy in PDGFRA Mutant GISTs.
Ravegnini G et al.
International Journal of Molecular Sciences, 2022
Correlation of treatment outcome in sanger/RT‑qPCR KIT/PDGFRA wild‑type metastatic gastrointestinal stromal tumors with next‑generation sequencing results: A single‑center report.
Unk M et al.
Oncology Reports, 2022
Oncogenic driver mutations predict outcome in a cohort of head and neck squamous cell carcinoma (HNSCC) patients within a clinical trial.
Fernández-Mateos J et al.
Scientific Reports, 2020
33024167 (PubMed )
Supplement: 41598_2020_72927_MOESM2_ESM.xlsx › Sheet1
Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours.
Bombac A et al.
International Journal of Oncology, 2020
Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation.
Indio V et al.
Frontiers in Immunology, 2020
Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors.
Pantaleo MA et al.
Epigenomics, 2016
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST).
Nannini M et al.
Bmc Cancer, 2014
Dystrophin deregulation is associated with tumor progression in KIT/PDGFRA mutant gastrointestinal stromal tumors.
Pantaleo MA et al.
Clinical Sarcoma Research, 2014
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.
Dai J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Differential expression of neural markers in KIT and PDGFRA wild-type gastrointestinal stromal tumours.
Pantaleo MA et al.
Histopathology, 2011
Insulin-like growth factor 1 receptor expression in wild-type GISTs: a potential novel therapeutic target.
Pantaleo MA et al.
International Journal of Cancer, 2009
Select a paper to view details